has been implicated in the treatment of certain eye diseases and conditions, including chronic anterior uveitis, an inflammatory condition of the vascular layer, particularly the iris.
In a small study, curcumin (375 mg t.i.d.) was administered orally for 12 weeks to 32 patients with chronic anterior uveitis. The participants were divided into two groups; the first received only curcumin while the second was treated with a combination of curcumin and antituber- cular therapy. All patients treated with curcumin alone improved, compared with a response rate of 86% among those receiving the combination therapy (42). Recently, a study was conducted on curcumin’s potential to treat dry eye disease and to protect against hyperosmosis-induced IL-1β elevation via MAPK pathways in human corneal epithelial cells. Human corneal epithelial cells cultured in the hyperosmotic medium for 24 h showed an increase of IL-1β, IL-6 and TNF-α levels. Curcumin (1–30 µM) did not affect the viability of cultured corneal epithelial cells, but pretreatment with curcumin (5 µM) completely abolished the increased production of IL-1β, p38 phosphorylation and NF-κB induced by the hyperosmotic medium (43). These studies suggest that curcumin may be an effective therapeutic for a variety of inflammatory eye conditions.
Shehzad A, Lee YS: Curcumin: multiple molecular targets mediate multiple
pharmaological actions -- a review. Drugs of the Future 2010;35:113-119.